Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2020 Results Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Judy Chiao - Vice President of Clinical Development and Regulatory Affairs Conference Call Participants Jonathan Aschoff - Roth Capital Partners Wangzhi Li - Ladenburg Kumar Raja - Brooklyn Capital Markets Operator G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ | --- | --- | |-------------------------------------------------------------------------|-------------------------| | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 00‑50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 91‑1707622 (State or Other Jurisdiction of Incorp ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2019 Results Conference Call February 26, 2020 4:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Dr. Judy Chiao - Vice President of Clinical Development and Regulatory Affairs Conference Call Participants Wangzhi Li - Ladenburg Thalmann Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Fourth Quar ...

Translating cancer biology into medicines NASDAQ CYCC – BIOCEO Conference February 10, 2020 Disclaimer | --- | --- | |-------------------------------------------------------------------------------------|---------------| | | | | This presentation contains forward-looking statements | within the | | meaning of the "safe harbor" provisions of the Private Securities | Litigation | | Reform Act of 1995 about financial results and estimates, | business | | strategy, clinical trial plans and research and developm ...

Translating cancer biology into medicines NASDAQ CYCC Biotech Showcase - January 13, 2020 Disclaimer | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------| | | | | This presentation contains forward-looking statements within | the meaning | | of the "safe harbor" provisions of the Private Securities | Litigation Reform | | Act of 1995 about financi ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2019 Earnings Conference Call November 13, 2019 4:30 PM ET Company Participants Jan Medina – Russo Partners LLC Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President-Finance and Chief Operating Officer Judy Chiao – Vice President-Clinical Development and Regulatory Affairs Conference Call Participants Wangzhi Li – Ladenburg Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Third Quarter 2019 Results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CYCC The Nasdaq Stock Market LLC Preferred Stock, $0.001 par value CYCCP The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

CYC 682 Translating cancer biology into medicines NASDAQ CYCC September 2019 Disclaimer | --- | --- | |--------------------------------------------------------------------------------------|---------------| | | | | This presentation contains forward-looking statements | within the | | meaning of the "safe harbor" provisions of the Private | Securities | | Litigation Reform Act of 1995 about financial results and | estimates, | | business strategy, clinical trial plans and research and | development | | prog ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2019 Results Earnings Conference Call August 13, 2019 4:30 PM ET Company Participants Paul McBarron - Executive VP of Finance, CFO, COO, Secretary & Executive Director Spiro Rombotis - President, CEO & Executive Director Alexander Fudukidis - IR, Russo Partners LLC Conference Call Participants Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Second Quarter 2019 Results Conference Call and Webcast. (Operator Instructions) The company will al ...